A study by using mouse model with immune-cold phenotype has demonstrated that the therapeutic combination of TGF-β1 blocking and PD-L1 inhibitor therapy reduced TGF-β1 signal transmission in stromal cells, increased the probability of T cells penetrating into tumor center, and stimulated strong anti-tumor immunity and mediated tumor regression [79]. The gene discussed is CD274; the disease is neoplasm.